Elevation Oncology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Tang Capital Management and affiliates report a 4.997% beneficial ownership stake in Elevation Oncology, Inc., primarily through exercisable warrants.
Frazier Life Sciences and its affiliates have reported a complete divestment of their beneficial ownership in Elevation Oncology, Inc., reducing their stake to 0.0%.
SCHEDULE 13G/A: BlackRock Discloses 0.6% Passive Stake in Elevation Oncology
BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.6% of Elevation Oncology, Inc.'s common stock as of June 30, 2025.
SCHEDULE 13G/A: Biotechnology Value Fund Group Discloses 7.0% Passive Stake in Elevation Oncology, Inc. via Warrants
A group of investment entities led by Biotechnology Value Fund and Mark N. Lampert has disclosed a combined beneficial ownership of 7.0% in Elevation Oncology, Inc., primarily through exercisable warrants.
Tang Capital Management, LLC and its affiliated entities, including Kevin Tang, have disclosed a continued passive beneficial ownership of 9.99% in Elevation Oncology, Inc., comprising common stock and currently exercisable warrants.
SCHEDULE 13G/A: Farallon Capital Entities Report Zero Beneficial Ownership in Elevation Oncology, Inc.
Farallon Capital and its affiliated entities have filed an amended Schedule 13G, indicating they no longer beneficially own any shares of Elevation Oncology, Inc.'s common stock as of March 31, 2025.
BML Investment Partners, L.P. has reported a 9.9% beneficial ownership stake in Elevation Oncology, Inc., indicating a passive investment.
Logos Global Management LP and its affiliated entities have filed an amended Schedule 13G, indicating they no longer hold any beneficial ownership in Elevation Oncology, Inc. as of December 31, 2024.
SCHEDULE 13G/A: Goldman Sachs Discloses 2.8% Passive Stake in Elevation Oncology
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting a passive beneficial ownership of 2.8% in Elevation Oncology, Inc. as of December 31, 2024.
Farallon Capital and its affiliated entities, including various funds and managing members, have filed an amended Schedule 13G reporting a collective beneficial ownership of 6% in Elevation Oncology, Inc. as of December 31, 2024.
BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.4% of Elevation Oncology, Inc.'s common stock as of December 31, 2024.
The Vanguard Group has filed a Schedule 13G, reporting a passive beneficial ownership of 4.41% in Elevation Oncology Inc. as of December 31, 2024.